8-K: PAVmed Subsidiary, Veris Health, Partners with Ohio State University Cancer Center for Pilot Program

Veris Health, a subsidiary of PAVmed, has signed a memorandum of understanding with The Ohio State University Comprehensive Cancer Center to implement a pilot program for its Veris Cancer Care Platform.

Summary

• PAVmed's subsidiary, Veris Health, has partnered with The Ohio State University Comprehensive Cancer Center to pilot the Veris Cancer Care Platform.
• The pilot program will enroll cancer patients on the Veris platform, which includes remote physiological data collection, symptom reporting, telehealth, and electronic health record integration.
• The Veris platform aims to enhance personalized cancer care through early detection of complications, reduced hospitalizations, and data-driven risk management.
• Patients will receive a VerisBox with connected health devices that transmit data to a cloud-based portal, and a patient app for symptom reporting.
• Veris is also developing an implantable physiological monitor to further enhance the platform's capabilities.

Sentiment

Score: 7

Explanation: The document is positive due to the partnership with a major cancer center and the potential of the Veris platform, but there are also risks and uncertainties associated with the company's future.

Positives

• The partnership with a prestigious institution like The Ohio State University Comprehensive Cancer Center validates Veris' technology.
• The Veris Cancer Care Platform has the potential to improve patient outcomes and reduce healthcare costs.
• The platform's comprehensive features, including remote monitoring and telehealth, offer convenience and accessibility for patients.
• The development of an implantable monitor could provide more reliable and continuous data collection.
• The platform aims to increase patient and provider satisfaction.

Risks

• The success of the pilot program is not guaranteed and may not lead to widespread adoption of the platform.
• The company faces risks related to regulatory approvals, market acceptance, and competition.
• The company may need to raise additional funding to support the development and commercialization of its products.
• There are risks associated with the volatility of PAVmed's stock price and general economic conditions.

Future Outlook

The company anticipates completing a successful pilot program and offering enhanced personalized cancer care to patients at The Ohio State University Comprehensive Cancer Center. They also plan to continue developing the implantable physiological monitor.

Management Comments

• Lishan Aklog, M.D., PAVmed's Chairman and CEO, stated they are excited to work with a renowned institution at the forefront of cancer care.
• Gary K. Manning, Veris President, said their vision is to enhance personalized cancer care through cutting-edge digital health tools.
• David Cohn, M.D., M.B.A., interim chief executive officer and chief medical officer at The James Cancer Hospital and Solove Research Institute, stated that remote monitoring allows for the integration of expert oncology care in a patient's home.

Industry Context

This announcement aligns with the growing trend of using digital health technologies to improve patient care and outcomes, particularly in chronic disease management like cancer. The partnership with a major cancer center highlights the increasing acceptance of remote patient monitoring in healthcare.

Comparison to Industry Standards

• The Veris Cancer Care Platform is similar to other remote patient monitoring solutions in the market, such as those offered by companies like BioTelemetry and Teladoc Health, but focuses specifically on cancer care.
• The development of an implantable physiological monitor is a unique feature that could differentiate Veris from its competitors.
• The partnership with The Ohio State University Comprehensive Cancer Center is a significant step for Veris, as it provides access to a large patient population and a prestigious research institution, similar to how other companies partner with large hospital networks.
• The platform's focus on personalized care and data-driven risk management is in line with industry trends towards more patient-centric healthcare solutions.

Stakeholder Impact

• Shareholders may view this partnership positively, potentially increasing the value of PAVmed stock.
• Employees of Veris Health may benefit from the growth and success of the company.
• Cancer patients may benefit from the improved care and convenience offered by the Veris platform.
• The Ohio State University Comprehensive Cancer Center may benefit from the use of the Veris platform to improve patient outcomes and efficiency.

Next Steps

• Veris and The Ohio State University Comprehensive Cancer Center will implement the pilot program.
• Veris will continue to develop its implantable physiological monitor.
• The company will seek to expand the use of the Veris Cancer Care Platform to other cancer centers and oncology practices.

Key Dates

Keywords

Veris Health, PAVmed, Cancer Care Platform, Remote Patient Monitoring, Digital Health, Ohio State University, Pilot Program, Telehealth, Implantable Monitor, Oncology